Xconomy National

Archives

by in

Entry	Author	Date	Location
Seattle Genetics Sees Updated Side Effect Warning in Drug Label	Luke Timmerman	01/13/12	Seattle
Xconomy Seattle’s Top 12 Life Sciences Stories of the Year	Luke Timmerman	12/28/11	Seattle
The Year in Seattle Biotech: Lots of Acquisitions, Few New Startups	Luke Timmerman	12/22/11	Seattle
Seattle Genetics, Millennium Look to Broaden Reach of Hodgkin’s Drug	Luke Timmerman	12/09/11	Seattle
Scale Venture Partners Gives Up On Healthcare & Life Sciences Investing	Wade Roush	11/08/11	San Francisco
Groupon: The IPO With More Sizzle, and Money, Than the Entire Biotech IPO Class of 2011	Luke Timmerman	11/07/11	National
Seattle Genetics Beats Expectations With $10M Sales in Lymphoma Drug Debut	Luke Timmerman	11/03/11	Seattle
Analyst: Seattle Genetics on Pace to Smash Wall Street Forecast with Lymphoma Drug Rollout	Luke Timmerman	10/20/11	Seattle
Fearless Fantasy Football, Uh, I Mean Biotech, Predictions for the Season Ahead	Luke Timmerman	09/06/11	National
Seattle Genetics’ Market Debut, Pathway Gets Bought, Theraclone’s Latest Trick Against HIV, & More Seattle-Area Life Sciences News	Luke Timmerman	08/25/11	Seattle
Video: Seattle Genetics CEO Makes the Case for a $100K Cancer Drug	Luke Timmerman	08/22/11	Seattle
Seattle Genetics Sets Lymphoma Drug Price at $13,500 Per Dose	Luke Timmerman	08/22/11	Seattle
Seattle Genetics: The Next Litmus Test for High Priced Cancer Drugs	Luke Timmerman	08/22/11	National
Seattle Genetics Wins FDA Approval of First Drug, a New Treatment for Lymphomas	Luke Timmerman	08/19/11	Seattle
SeaGen Passes FDA Panel, Ken Stuart’s Journey to Seattle Biomed, the Latest M&A Obsession, & More Seattle-Area Life Sciences News	Luke Timmerman	07/21/11	Seattle
Stop the M&A Obsession: Biotech Needs More Companies to Stay Independent	Luke Timmerman	07/18/11	National
Seattle Genetics Lymphoma Drug Gets Second Green Light from FDA Panel	Luke Timmerman	07/14/11	Seattle
Seattle Genetics Wins Unanimous OK for Lymphoma Drug from FDA Panel	Luke Timmerman	07/14/11	Seattle
SeaGen’s Big Day at the FDA, Hutch Nabs $20M HIV Grant, Allozyne’s Nasdaq Plan, & More Seattle-Area Life Sciences News	Luke Timmerman	07/14/11	Seattle
Insider Trader Pleads Guilty in SeaGen Case	Luke Timmerman	07/12/11	Seattle
Seattle Genetics’ New ‘Empowered Antibody’ Looks Clean in FDA Staff Documents	Luke Timmerman	07/12/11	Seattle
Seattle Genetics’ FDA Panel Preview: What You Need to Know This Week	Luke Timmerman	07/12/11	Seattle
SeaGen Preserves Science Culture, Dendreon Sways Medicare, NanoString’s Financing, & More Seattle-Area Life Sciences News	Luke Timmerman	07/07/11	Seattle
Seattle Genetics, On the Verge of Going Commercial, Seeks to Keep Its Scientific Soul	Luke Timmerman	07/05/11	Seattle
Allozyne’s Backdoor IPO, Sound Pharma Fights iPod Deafness, Mirina Vs. Marina Ends, & More Seattle-Area Life Sciences News	Luke Timmerman	06/23/11	Seattle
Cyterix Develops New Twist on an Old Idea, With ‘Smart Bomb’ Cancer Drugs	Luke Timmerman	06/22/11	San Francisco
SeaGen Promotes Dobmeier	Luke Timmerman	06/17/11	Seattle
ASCO Wrap-Up, Pathway Medical Grinds It Out, Gates Foundation’s New Digs, & More in Seattle-Area Life Sciences News	Luke Timmerman	06/09/11	Seattle
ASCO Wrap-Up: The Skinny on Cancer News From All Corners of the U.S.	Luke Timmerman	06/07/11	National
Resolve Maps Out New Biotech Model, SeaGen Expands, Schadt Heads East, & More in Seattle-Area Life Sciences News	Luke Timmerman	05/19/11	Seattle
Page 1 of 7	next page »